You are here: Industry Insights > SPI-1005

News List

Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment contractpharma
April 08, 2021
Sound Pharmaceuticals, Inc. (SPI) has received a Cooperative Grant award from the National Center for Advancing Translational Sciences (NCATS) at the NIH for $3.1 milion to support the testing of SPI-1005 in two Phase 2 clinical trials for the ...
FDA Clears SPI’s Ebselen for Phase II COVID-19 Trials contractpharma
September 01, 2020
SPI-1005 is a novel anti-inflammatory drug which was recently shown to inhibit nCoV2 activity and viral replication.
Sound Pharma Advances Pivotal Phase 3 Clinical Trials in Meniere's Disease americanpharmaceuticalreview
June 17, 2020
Sound Pharmaceuticals announced the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere's Disease (STOPMD-3).
University of Oxford, Sound Pharmaceuticals Complete Phase 2 Bipolar Disorder Study americanpharmaceuticalreview
May 11, 2020
The University of Oxford and Sound Pharmaceuticals (SPI) announced the successful completion of a Phase 2a study testing SPI-1005 as a new treatment for bipolar disorder (BPD).
FDA Grants Fast Track Designation for Meniere's Disease Treatment americanpharmaceuticalreview
September 19, 2019
Sound Pharmaceuticals announced the FDA's Division of Neurology Products has approved its request for Fast Track Designation (FTD) involving SPI-1005 in the treatment of Meniere's Disease (MD).